Longest follow up trial of Merck’s Keytruda sets new standard for five year survival in lung cancer
pharmafile | June 3, 2019 | News story | Sales and Marketing | KEYNOTE, MSD, Merck, keytruda, lung cancer
Nearly a quarter of previously untreated lung cancer patients who took Keytruda (Pembrolizumab) were alive after five years, according to the results of the longest follow-up trial for Merck’s cancer immunotherapy.
In total, 23.2% of treatment naïve patients with advanced non-small cell lung cancer (NSCLC) were alive after five years.
The data from the phase 3 KEYNOTE trial of 616 patients showed that 23.2% of previously untreated and 15.5% of previously treated patients lived for more than five years after receiving MSD’s immunotherapy.
“Lung cancer is the leading cause of cancer death, and historically, the five-year survival rate has been around 5% for patients in the U.S. with advanced non-small cell lung cancer,” said Edward B. Garon, MD, MS, associate professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles.
“As a treating physician, it is encouraging to see the results of KEYNOTE-001, in which pembrolizumab showed a five-year overall survival rate of 23.2% in treatment-naïve patients and 15.5% in previously treated patients.”
Among 60 patients who received two or more years of treatment with Keytruda, the five year overall survival rate was 78.6% in treatment naïve patients and 75.8% in previously treated patients.
“Five-year survival is a significant milestone for patients with advanced non-small cell lung cancer, and it is encouraging to see the long-term overall survival rates from our first KEYNOTE study,” said Dr. Roy Baynes, senior vice president and chief medical officer, Merck Research Laboratories.
“These five-year data provide important insights into the long-term safety and efficacy of KEYTRUDA in patients with advanced non-small cell lung cancer.”
Louis Goss
Related Content
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
Cizzle Biotechnology expands US rollout of lung cancer blood test
Cizzle Biotechnology has launched the commercial rollout of its CIZ1B Biomarker Blood Test for lung …
SMC accepts amivantamab and lazertinib for EGFR-positive lung cancer
The Scottish Medicines Consortium (SMC) has accepted Rybrevant (amivantamab) in combination with Lazcluze (lazertinib) for …
